Improvement of the novel inhibitor for Mycobacterium enoyl-acyl carrier protein reductase (InhA): a structure–activity relationship study of KES4 assisted by in silico structure-based drug screening
暂无分享,去创建一个
H. Sakamoto | J. Sacchettini | F. Berenger | S. Aoki | J. Taira | Tomohiro Umei | K. Inoue | Mitsuru Kitamura
[1] H. Sakamoto,et al. Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening , 2017, The Journal of Antibiotics.
[2] H. Sakamoto,et al. In silico structure-based drug screening of novel antimycobacterial pharmacophores by DOCK-GOLD tandem screening , 2017, International journal of mycobacteriology.
[3] R. Horton,et al. Tuberculosis—getting to zero , 2015, The Lancet.
[4] G. Sotgiu,et al. Tuberculosis treatment and drug regimens. , 2015, Cold Spring Harbor perspectives in medicine.
[5] H. Sakamoto,et al. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach. , 2015, European journal of medicinal chemistry.
[6] O. N. de Souza,et al. Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies. , 2015, European journal of medicinal chemistry.
[7] Shunsuke Aoki,et al. Identification of Novel Potential Antibiotics against Staphylococcus Using Structure-Based Drug Screening Targeting Dihydrofolate Reductase , 2014, J. Chem. Inf. Model..
[8] S. Aoki,et al. Computational medicinal chemistry for rational drug design: Identification of novel chemical structures with potential anti-tuberculosis activity. , 2013, Current topics in medicinal chemistry.
[9] Hiroshi Sakamoto,et al. Identification of Compounds with Potential Antibacterial Activity against Mycobacterium through Structure-Based Drug Screening , 2013, J. Chem. Inf. Model..
[10] Shunsuke Aoki,et al. Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library. , 2013, European journal of medicinal chemistry.
[11] Gulcin Gulten,et al. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis , 2010, Molecular microbiology.
[12] P. Constant,et al. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents. , 2010, European journal of medicinal chemistry.
[13] Philippe Glaziou,et al. Tuberculosis control and elimination 2010–50: cure, care, and social development , 2010, The Lancet.
[14] R. Horton,et al. Tuberculosis—time to accelerate progress , 2010, The Lancet.
[15] C. Dye,et al. The Population Dynamics and Control of Tuberculosis , 2010, Science.
[16] Charles W. Schmidt,et al. TOX 21: New Dimensions of Toxicity Testing , 2009, Environmental health perspectives.
[17] T. Collier,et al. The Synergistic Toxicity of Pesticide Mixtures: Implications for Risk Assessment and the Conservation of Endangered Pacific Salmon , 2008, Environmental health perspectives.
[18] Peter J Tonge,et al. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. , 2007, Current topics in medicinal chemistry.
[19] Robert Stroud,et al. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. , 2006, Journal of medicinal chemistry.
[20] Fernanda Canduri,et al. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis. , 2006, Journal of molecular biology.
[21] Jean-Loup Faulon,et al. The Signature Molecular Descriptor. 1. Using Extended Valence Sequences in QSAR and QSPR Studies , 2003, J. Chem. Inf. Comput. Sci..
[22] James C. Sacchettini,et al. Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.
[23] S. Parikh,et al. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. , 2000, Biochemistry.
[24] P. McDermott,et al. Genetic Evidence that InhA of Mycobacterium smegmatis Is a Target for Triclosan , 1999, Antimicrobial Agents and Chemotherapy.
[25] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[26] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[27] J C Sacchettini,et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.
[28] W. Jacobs,et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.
[29] Leo Breiman,et al. Bagging Predictors , 1996, Machine Learning.
[30] John C. Platt,et al. Probabilistic Outputs for Support vector Machines and Comparisons to Regularized Likelihood Methods , 1999 .
[31] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[32] H. Nikaido,et al. The envelope of mycobacteria. , 1995, Annual review of biochemistry.